New York

Glue42 democratizes the financial desktop with the release of Glue42 Core

Thursday, April 2, 2020 - 8:00am

LONDON, April 2, 2020 /PRNewswire/ -- Glue42 , the company that delivers integrated desktop experiences to financial institutions globally, today announced it has released Glue42 Core, an open-source, fully functional platform for web application interoperability.

Key Points: 
  • LONDON, April 2, 2020 /PRNewswire/ -- Glue42 , the company that delivers integrated desktop experiences to financial institutions globally, today announced it has released Glue42 Core, an open-source, fully functional platform for web application interoperability.
  • Glue42 Core leverages Progressive Web Applications (PWA), a modern web technology to deliver a native app-like experience to users without any local install.
  • Glue42 Core is the first solution to remove these barriers and can be used on desktops within the enterprise or by clients.
  • For those interested in the journey that led to Glue42 Core, Glue42 will be hosting a launch webinar on April 8,2020 at 11:00am ET.

Lemonade Launches in the Netherlands

Thursday, April 2, 2020 - 8:30am

Consumers in the Netherlands can now get contents and liability insurance instantly, anytime, and from any device as well as file claims and get paid in seconds through the Lemonade app.

Key Points: 
  • Consumers in the Netherlands can now get contents and liability insurance instantly, anytime, and from any device as well as file claims and get paid in seconds through the Lemonade app.
  • View the full release here: https://www.businesswire.com/news/home/20200402005116/en/
    Todays launch marks the second EU country Lemonade has entered, following Germany last year.
  • Lemonade offers homeowners and renters insurance in the United States, and contents and liability insurance in Germany and the Netherlands, through its full-stack insurance carriers.
  • Lemonade is currently available in Germany, the Netherlands and most of the United States, and continues to expand globally.

Cynopsis Announces New Webinar on Esports Betting on April 7

Thursday, April 2, 2020 - 6:30am

NEW YORK, April 2, 2020 /PRNewswire-PRWeb/ --Cynopsis Esports will host the April 7 webinar, The New Opportunity: Esports Betting .

Key Points: 
  • NEW YORK, April 2, 2020 /PRNewswire-PRWeb/ --Cynopsis Esports will host the April 7 webinar, The New Opportunity: Esports Betting .
  • Produced in partnership with the Nevada Esports Alliance and Esports Business Summit, learn how esports can affect the betting industry and its odds of long-term success.
  • In this webinar, you will learn:
    Register for the Cynopsis Esports webinar, " The New Opportunity: Esports Betting ."
  • The Cynopsis family of products includes the media industry's most-read daily, Cynopsis, plus sister daily Cynopsis Sports; weekly Esports, Media Tech, the Cynopsis Jobs board and special reports.

Sensorion Reports Full-year 2019 Financial Results and Business Update

Thursday, April 2, 2020 - 6:30am

As part of this consortium, Sensorion will receive up to 5.6 million over the duration of the project contingent on milestones completion.

Key Points: 
  • As part of this consortium, Sensorion will receive up to 5.6 million over the duration of the project contingent on milestones completion.
  • SENS-111 (Seliforant) was safe and well tolerated in a Phase 2 proof-of-concept study for the treatment of acute unilateral vestibulopathy (AUV).
  • However, it did not meet the primary endpoint of vertigo intensity and Sensorion stopped all development activities for SENS-111.
  • On the 13th of March, Sensorion made an update on timelines for the ongoing Phase 2 study of SENS-401 to treat Sudden Sensorineural Hearing Loss (SSNHL).

Open Letter to Stakeholders

Thursday, April 2, 2020 - 2:43am

Our top 10 borrowers represent approximately 24% of investments at fair value, the largest being 4.1%.

Key Points: 
  • Our top 10 borrowers represent approximately 24% of investments at fair value, the largest being 4.1%.
  • With respect to our joint ventures, both are focused almost exclusively on either first lien or unitranche loans and are diversified within the ventures.
  • Although long-term impacts are still very uncertain, Portman Ridge has limited exposure to the sectors that have experienced immediate impacts.
  • PTMNs investment activities are managed by its investment adviser, Sierra Crest Investment Management LLC, an affiliate of BC Partners Advisors, LP, (the Adviser).

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Paysign, Inc. of Class Action Lawsuit and Upcoming Deadline - PAYS

Thursday, April 2, 2020 - 1:19am

If you are a shareholder who purchased Paysign securities during the class period, you have until May 18, 2020, toask the Court to appoint you as Lead Plaintiff for the class.

Key Points: 
  • If you are a shareholder who purchased Paysign securities during the class period, you have until May 18, 2020, toask the Court to appoint you as Lead Plaintiff for the class.
  • To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Paysign provides prepaid card programs and processing services under the Paysign brand to corporations, government agencies, universities, and other organizations.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Exela Technologies, RTI Surgical, DouYu, and AnaptysBio and Encourages Investors to Contact the Firm

Thursday, April 2, 2020 - 1:00am

The next day, Exela issued another press release containing an update regarding their delayed filing.

Key Points: 
  • The next day, Exela issued another press release containing an update regarding their delayed filing.
  • The Company disclosed that the cause of the delay was that its Audit Committee was investigating the Companys revenue recognition practices.
  • As a result of defendants' misrepresentations, shares of AnaptysBio common stock traded at artificially inflated prices throughout the Class Period.
  • For more information on the AnaptysBio class action go to: https://bespc.com/ANAB
    About Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sasol Limited and Spirit AeroSystems and Encourages Investors to Contact the Firm

Thursday, April 2, 2020 - 12:44am

Following these disclosures, Sasols share price fell $3.53 per share, or 10.99%, to close at $28.60 per share on June 6, 2016.

Key Points: 
  • Following these disclosures, Sasols share price fell $3.53 per share, or 10.99%, to close at $28.60 per share on June 6, 2016.
  • Following these disclosures, Sasols share price fell $4.50 per share, or 14.93%, to close at $25.64 per share on May 22, 2019.
  • For more information on the Sasol class action go to: https://bespc.com/ssl
    On January 30, 2020, Spirit issued a press release announcing executive officer changes.
  • For more information on the Spirit AeroSystems class action go to: https://bespc.com/spr
    About Bragar Eagel & Squire, P.C.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of  LogicBio Therapeutics, Inc. – LOGC

Thursday, April 2, 2020 - 12:27am

NEW YORK, April 01, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (LogicBio or the Company) (NASDAQ:LOGC).

Key Points: 
  • NEW YORK, April 01, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (LogicBio or the Company) (NASDAQ:LOGC).
  • Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.
  • The investigation concerns whether LogicBio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO

Thursday, April 2, 2020 - 12:21am

NEW YORK, April 01, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (Inovio or the Company) (NASDAQ:INO).

Key Points: 
  • NEW YORK, April 01, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (Inovio or the Company) (NASDAQ:INO).
  • Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.
  • On March 3, 2020, Inovio issued a press release entitled Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.